BPTH (Bio-Path Holdings, Inc) Pangali Forward P/E

Bio-Path Holdings (BPTH) combines a closed RNA therapy ecosystem with the scalable production of DNA drugs. The company's forward P/E ratio on the GURU.Markets chart reconciles these approaches, while the 0.00 level captures fresh values. Currently in the pre-revenue stage, Bio-Path Holdings is competing for priority in clinical trials using its proprietary targeted therapy methods.

Rega marang bathi mangsa ngarep: Bio-Path Holdings, Inc. (BPTH) kanggo 04.07.2022 - 01.03.2025

Ringkesan rincian data analitis Bio-Path Holdings, Inc (BPTH)

- rega saiki lan proyeksi nilai saham:

Kutipan saham Bio-Path Holdings, Inc.|BPTH - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Bio-Path Holdings Inc.|BPTH - Nilai Total Perusahaan

- informasi kapitalisasi buku:

Aset Bersih saben Siji Saham Bio-Path Holdings|BPTH - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku biopathholdings.com|BPTH - Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas Bio-Path Holdings|BPTH - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Bio-Path Holdings|BPTH - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Bio-Path Holdings Inc.|BPTH - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Bio-Path Holdings|Likuiditas cepet biopathholdings.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

BPTH - Penghasilan resik perusahaan|Bathi mangsa ngarep Bio-Path Holdings|BPTH - Rasio kapitalisasi marang bathi resik|Rega marang bathi mangsa ngarep Bio-Path|BPTH - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Bio-Path Holdings Inc.|BPTH - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Bio-Path Holdings|BPTH - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan biopathholdings.com|BPTH - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Bio-Path Holdings

Ringkesan analitik perusahaan:Bio-Path Holdings, Inc.

Produk mawa merek Bio-Path Holdings, Inc

Bio-Path Holdings (BPTH) reliance on external CROs and CMOs for oncology drug development makes future profits sensitive to the operational risks of contractors. By analyzing the company's forward P/E, an investor compares the current share price with expected earnings to determine the extent of the embedded premium for business scalability; deviations on this chart signal an overvaluation or undervaluation of the issuer's expansion potential.

Perusahaan pesaing